The present and the future in the diagnosis and management of celiac disease

Gastroenterology Report

Volumn 3, Issue 1, 2015, Pages 3-11

  Castillo, Natalia E ^a   Theethira, Thimmaiah G ^a   Leffler, Daniel A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Celiac disease; Gluten free diet

Indexed keywords

EID: 84931831828     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou065     Document Type: Review

References (78)

1. Ludvigsson JF, Leffler DA, Bai JC et al. The Oslo definitions for coeliac disease and related terms. Gut 2013;62:43-52.
2. Rostom A, Murray JA and Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981-2002.
3. Platt SG and Kasarda DD. Separation and characterization of - gliadin fractions. Biochim Biophys Acta 1971;243:407-15.
4. Koskinen O, Villanen M, Korponay-Szabo I et al. Oats do not induce systemic or mucosal autoantibody response in children with coeliac disease. J Pediatr Gastroenterol Nutr 2009;48:559-65.
5. Reilly NR, Fasano A and Green PH. Presentation of celiac disease. Gastrointest Endosc Clin N Am 2012;22:613-21.
6. Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000;119:234-42.
7. Bourgey M, Calcagno G, Tinto N et al. HLA related genetic risk for coeliac disease. Gut 2007;56:1054-9.
8. Green PH and Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43.
9. Nilsen EM, Jahnsen FL, Lundin KE et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998;115:551-63.
10. Szebeni B, Veres G, Dezsofi A et al. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr 2007;45:187-93.
11. Maiuri L, Ciacci C, Auricchio S et al. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 2000;119: 996-1006.
12. Meresse B, Chen Z, Ciszewski C et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-66.
13. Malamut G, El Machhour R, Montcuquet N et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010;120:2131-43.
14. Schuppan D and Zimmer KP. The diagnosis and treatment of celiac disease. Dtsch Arztebl Int 2013;110:835-46.
15. Leffler DA and Schuppan D. Update on serological testing in celiac disease. Am J Gastroenterol 2010;105:2520-24.
16. Accomando S and Cataldo F. The global village of celiac disease. Dig Liver Dis 2004;36:492-8.
17. Makharia GK, Mulder CJ, Goh KL et al. Issues associated with the emergence of coeliac disease in the Asia-Pacific region: a working party report of the World Gastroenterology Organization and the Asian Pacific Association of Gastroenterology. J Gastroenterol Hepatol 2014;29:666-77.
18. Rubio-Tapia A, Ludvigsson JF, Brantner TL et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107:1538-44; quiz 1537, 1545.
19. Ukkola A, Kurppa K, Collin P et al. Use of health care services and pharmaceutical agents in coeliac disease: a prospective nationwide study. BMC Gastroenterol 2012;12:136.
20. Theethira TG and Kelly CP. Coeliac disease. Missing villi? The search for coeliac disease in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2014;11:204-5.
21. Strong K, Wald N, Miller A et al. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. J Med Screen 2005;12:12-19.
22. NIH Consensus Development Conference on Celiac Disease. NIH Consens State Sci Statements 2004;21:1-23.
23. Rubio-Tapia A, Hill ID, Kelly CP et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76; quiz 677.
24. Kurppa K, Paavola A, Collin P et al. Benefits of a gluten-free diet for asymptomatic patients with serological markers of celiac disease. Gastroenterology 2014;147:610-17.
25. Hernandez L and Green PH. Extra-intestinal manifestations of celiac disease. Curr Gastroenterol Rep 2006;8:383-9.
26. Naiyer AJ, Hernandez L, Ciaccio EJ et al. Comparison of commercially available serological kits for the detection of celiac disease. J Clin Gastroenterol 2009;43:225-32.
27. Rostom A, Dube C, Cranney A et al. The diagnostic accuracy of serological tests for celiac disease: a systematic review. Gastroenterology 2005;128(4 Suppl 1):S38-46.
28. Kwiecien J, Karczewska K, Lukasik M et al. Negative results of antiendomysial antibodies: long term follow up. Arch Dis Child 2005;90:41-2.
29. Schuppan D, Junker Y and Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137: 1912-33.
30. Meini A, Pillan NM, Villanacci V et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996;77:333-6.
31. Wang N, Truedsson L, Elvin K et al. Serological assessment for celiac disease in IgA deficient adults. PLoS One 2014;9:e93180.
32. Popp A, Jinga M, Jurcut C et al. Fingertip rapid point-of-care test in adult case-finding in coeliac disease. BMC Gastroenterol 2013;13:115.
33. Mooney PD, Kurien M, Evans KE et al. Point-of-care testing for celiac disease has a low sensitivity in endoscopy. Gastrointest Endosc 2014;80:456-62.
34. Karell K, Louka AS, Moodie SJ et al. HLA types in celiac disease patients not carrying the DQA1∗05-DQB1∗02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003;64:469-77.
35. Kaukinen K, Partanen J, Maki M et al. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002;97:695-9.
36. Pallav K, Kabbani T, Tariq S et al. Clinical utility of celiac disease- associated HLA testing. Dig Dis Sci 2014;59:2199-206.
37. Lundin KE and Sollid LM. Advances in coeliac disease. Curr Opin Gastroenterol 2014;30:154-62.
38. Bao F, Green PH and Bhagat G. An update on celiac disease histopathology and the road ahead. Arch Pathol Lab Med 2012;136:735-45.
39. Leffler D, Schuppan D, Pallav K et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013;62:996-1004.
40. Tortora R, Russo I, De Palma GD et al. In vitro gliadin challenge: diagnostic accuracy and utility for the difficult diagnosis of celiac disease. Am J Gastroenterol 2012;107:111-17.
41. Vanga R, Kelly CP, Chen X et al. Ex vivo gluten challenge differentiates patients with celiac disease on a gluten free diet fromhealthy individuals. Gastroenterology 2014;146(5):S471.
42. Cronk DR, Houseworth TP, Cuadrado DG et al. Intestinal fatty acid binding protein (I-FABP) for the detection of strangulated mechanical small bowel obstruction. Curr Surg 2006;63:322-5.
43. Vreugdenhil AC, Wolters VM, Adriaanse MP et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011;46:1435-41.
44. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005;128(4 Suppl 1):S1-9.
45. Hammer ST and Greenson JK. The clinical significance of duodenal lymphocytosis with normal villous architecture. Arch Pathol Lab Med 2013;137:1216-19.
46. DeGaetani M, Tennyson CA, Lebwohl B et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol 2013;108:647-53.
47. Pallav K, Leffler DA, Tariq S et al. Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice. Aliment Pharmacol Ther 2012;35:380-90.
48. Gasbarrini G, Miele L, Corazza GR et al. When was celiac disease born?: the Italian case from the archeological site of Cosa. J Clin Gastroenterol 2010;44:502-3.
49. Kupfer SS and Jabri B. Pathophysiology of celiac disease. Gastrointest Endosc Clin N Am 2012;22:639-60.
50. Tommasini A, Not T and Ventura A. Ages of celiac disease: from changing environment to improved diagnostics. World J Gastroenterol 2011;17:3665-71.
51. Catassi C, Fabiani E, Iacono G et al. A prospective, doubleblind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007;85:160-6.
52. Akobeng AK and Thomas AG. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008;27:1044-52.
53. Leffler DA, DennisM, Hyett B et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007;5:445-50.
54. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-9.
55. Leffler DA, Edwards-George J, Dennis M et al. Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci 2008;53:1573-81.
56. Cranney A, Zarkadas M, Graham ID et al. The Canadian Celiac Health Survey. Dig Dis Sci 2007;52:1087-95.
57. Lee AR, Ng DL, Zivin J et al. Economic burden of a gluten-free diet. J Hum Nutr Diet 2007;20:423-30.
58. Peraaho M, Kaukinen K, Mustalahti K et al. Effect of an oatscontaining gluten-free diet on symptoms and quality of life in coeliac disease. A randomized study. Scand J Gastroenterol 2004;39:27-31.
59. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005;129:797-806.
60. van den Broeck HC, van Herpen TW, Schuit C et al. Removing celiac disease-related gluten proteins from bread wheat while retaining technological properties: a study with Chinese Spring deletion lines. BMC Plant Biol 2009;9:41.
61. M'hir S, Ziadi M, Chammem N et al. Gluten proteolysis as alternative therapy for celiac patients: A mini-review. African Journal of Biotechnology 2012;11:7323-30.
62. Tye-Din JA, Anderson RP, Ffrench RA et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010;134:289-95.
63. Siegel M, Garber ME, Spencer AG et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating- dose clinical trials. Dig Dis Sci 2012;57:440-50.
64. Lindfors K, Blomqvist T, Juuti-Uusitalo K et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8.
65. Tack JMvdW GJ, Kooy-Winkelaar EM, van Bergen J et al. Can Prolyl Endoprotease Enzyme Treatment Mitigate the Toxic Effect of Gluten in Celiac Patients? Gastroenterology 2010;138:S54.
66. Bethune MT and Khosla C. Oral enzyme therapy for celiac sprue. Methods Enzymol 2012;502:241-71.
67. Menard S, Lebreton C, Schumann M et al. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol 2012;180:608-15.
68. Sapone A, de Magistris L, Pietzak M et al. Zonulin up-regulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006;55:1443-9.
69. Gopalakrishnan S, Durai M, Kitchens K et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012;35:86-94.
70. Schumann M, Richter JF, Wedell I et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 2008;57:747-54.
71. Gopalakrishnan S, Tripathi A, Tamiz AP et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 2012;35:95-101.
72. Paterson BM, Lammers KM, Arrieta MC et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26:757-66.
73. Leffler DA, Kelly CP, Abdallah HZ et al. A randomized, doubleblind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012;107:1554-62.
74. Kelly CP, Green PH, Murray JA et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013;37:252-62.
75. Lohi S, Mustalahti K, Kaukinen K et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26:1217-25.
76. Rook GA. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 2012;42:5-15.
77. Summers RW, Elliott DE, Qadir K et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003;98: 2034-41.
78. Gillett HR, Arnott ID, McIntyre M et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002;122:800-5.